Which of the following relationship is incorrect?
A. Natalizumab for Multiple Sclerosis and Crohn’s disease; Side effect: multifocal leukoencephalopathy
B. Omalizumab for Allergic Asthma; Side effect: increased epithelial or solid organ cancers, anaphylaxis
C. Bevacizumab for colorectal, lung, breast or renal cell cancer; Side effect: hypotension and decreased risk of bleeding
D. Alemtuzumab for chronic lymphocytic leukemia; Side effect: cardiac arrest
Answer: C
Bevacizumab is associated with hypertension and increased risk of bleeding
Critical care physicians may sometimes receive patients who are on these monoclonal antibies. We can be at a loss learning the myriad of these names ending with -mab. A list of FDA-approved monoclonal antibodies can be found here at Wikepedia.
The current “big 5” therapeutic antibodies on the market are Bevacizumab (Avastin), Trastuzumab (Herceptin), Adalimumab (Humira) , Infliximab (Remicade) and Rituximab (Rituxan), which accounted for 80% of revenues in 2006.